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HIV patients infected through injected drug use have poorer prognosis than other groups.
We  evaluated the hematological alterations and rates of co-infections in injected drug use
patients  with AIDS. Injected drug use patients were younger, predominantly of male gender,
and  presented lower CD4, total lymphocyte, and platelet counts, but not neutrophil count,
than control group. Injected drug use patients had a higher rate of hepatitis C and mycobac-
teria  infection. Furthermore, all injected drug use patients with hemoglobin <10.0 g dL−1
and lymphocyte <1000 L−1 had CD4 count lower than 100 L−1. In conclusion, HIV-infectedInjected drug use
Anemia
HCV
Mycobacteria
injected  drug use patients constitute a special group of patients, and hemoglobin concen-
tration  and lymphocyte count can be used as surrogate markers for disease severity.
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Injected drug use is a risk factor for HIV infection and has
been  associated with poor outcome.1 Progression to AIDS
and  mortality rate are substantially higher in injected drug
users  (IDU).2,3 Many  aspects have been associated to this fact:
adverse  socioeconomic conditions, psychiatric disorders, poor
compliance with treatment, and medical restrictions in pre-
scribing  antiretroviral therapy, due to concerns of selecting of
multidrug-resistant HIV.3 Hepatitis co-infection is commoner
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Este é um artigo Open Access sob a licençain this population.2 HIV infection and AIDS are associated
with a wide spectrum of hematological abnormalities.4,5 Blood
cytopenias  can be found in most patients during disease
evolution.4 Their etiology is multifactorial and include the
direct  effect of HIV, opportunistic infections and malignancies,
or  therapies used in the management of AIDS.4 Progressive
depletion of CD4 lymphocytes is the hallmark of advanc-SP, Ribeirao Preto, São Paulo 14051-140, Brazil.
ing  HIV disease and leads to the immunosuppression.4 This
retrospective cross-sectional study evaluated the hematolog-
ical  particularities of HIV-infected IDU patients and rates of
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Table 1 – Patients’ characteristics.
IDU (n = 104) Non-IDU (n = 597) p-Value
Age (years) 40 (27–61) 43 (16–79) 0.001
Male gender (%) 86.5 (90) 57.1 (341) <0.0001
CD4 < 200 L−1 (%) 37.5 (39) 23.6 (141) 0.0049
Lymphocyte L−1 1600 (200–4100) 1700 (100–4300) 0.0363
Anemia (%) 44 (46) 36 (175) NS
Neutrophil L−1 2500 (400–15,200) 2800 (700–17,500) NS
Platelet L−1 213,500 (22,000–550,000) 230,500 (16,000–515,000) 0.0279
Hepatitis C (%) 45.2  (47) 16.6  (99) <0.0001
Mycobacterium  infection (%) 9.6 (10) 3.7  (22) 0.0177
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dIDU, injection drug user; NS, not signiﬁcant.
Values expressed as percentage (absolute number) or median (range)
epatitis and mycobacteria co-infections. Furthermore, we
ntended  to correlate these alterations with CD4 count, and
stablish  a surrogate marker of disease severity combining
he  results of hemoglobin concentration (Hb) and lymphocyte
ount.
aterials  and  methods
e  reviewed the data of 701 consecutive HIV-infected patients
≥16  years) followed at our institution, of which 14.8% (104)
eported  injected drug use (Table 1). The parameters recorded
ere  HIV-viral load, Hb, CD4, lymphocyte, neutrophil, and
latelet  counts. Blood cell and CD4 counts, and HIV viral load
uantiﬁcation were  performed as previously described.5 Ane-
ia  was  deﬁned as Hb < 12.0 g dL−1 for women  and <14.0 g dL−1
or men. Statistical analyses were performed using SAS® (ver-
ion  9.1).
This study was  approved by the institution Ethics Commit-
ee.
esults
edian ages of IDU and non-IDU groups were 40 (27–61)
nd  43 (16–79) years, respectively (p = 0.001). Men com-
rised 86.5% (90/104) of IDU patients and 57.1% (341/597) of
on-IDU  patients (p < 0.0001). CD4 count was  lower among
DU  than non-IDU patients. CD4 was  <200 dL−1 in 37.5%
39/104) and 23.6% (141/597) of IDU and non-IDU patients,
espectively (p = 0.0049). Medians of lymphocyte counts were
600  L−1 (200–4100 L−1) and 1700 L−1 (100–4300 L−1) for
DU and non-IDU groups, respectively (p = 0.0363). We  did
ot  ﬁnd a signiﬁcant association between viral load and
se  of injected drugs (p = 0.2192). A total of 37.7% (264/701)
f  the patients had anemia at the moment of analysis,
4% (46/104) among IDU group and 36% (175/432) among
on-IDU group (p = 0.15). Medians of Hb were  11.8 g dL−1
6.4–15.4 g dL−1) and 12.8 g dL−1 (6.7–15.9 g dL−1) for IDU
nd non-IDU women, respectively (p = 0.2587); and 14.3
6.7–18.7  g dL−1) and 14.4 g dL−1 (6.4–20 g dL−1) for IDU and
on-IDU men, respectively (p = 0.6664). Furthermore, all IDU
−1 −1ndividuals  with Hb <10 g dL and lymphocyte <1000 L
n = 10) presented a CD4 < 100 dL−1 (speciﬁcity 100%, sensitivity
9.4%,  positive predictive value (PPV) 100% and negative pre-
ictive  value (NPV) 67.3%). Among the non-IDU group, 81.8%(18/22) of the individuals with Hb < 10 g dL−1 and lympho-
cyte <1000 L−1 presented CD4 < 200 dL−1 (speciﬁcity 99.12%,
sensitivity 12.7%, PPV 81.8% and NPV 75.7%). Medians of neu-
trophil  counts were 2500 L−1 (400–15,200 L−1) and 2800 L−1
(700–17,500 L−1) for IDU and non-IDU groups, respectively
(p = 0.1674). Medians of platelet counts were  213,500 L−1
(22,000–550,000 L−1) and 230,500 L−1 (16,000–515,000 L−1)
for  IDU and non-IDU groups, respectively (p = 0.0279). After
excluding the patients with hepatitis C (HCV), we  did not
ﬁnd  a signiﬁcant association between platelet number and
injected  drug use (p = 0.6868). A total of 45.2% (47/104) of the
IDU  group had HCV infection, diagnosed by Elisa and con-
ﬁrmed  by PCR, in contrast to 11% among the non-IDU group
(p  < 0.0001). Chronic hepatitis B was  present in 9.6% of the IDU
and  4.8% of the non-IDU (p = 0.0622) groups. A total of 24%
(25/104)  of IDU and 16.6% (99/597) of non-IDU groups reported
poor  adherence to treatment (p = 0.071). Mycobacteria infec-
tion  was  diagnosed (8 in sputum, 1 in gastric ﬂuid and 1 by
lymph  node biopsy) in 9.6% (10/104; 6 tuberculosis) among
IDU  patients and in only 3.7% (22/597; 13 tuberculosis) in the
non-IDU  (p = 0.0177) group. We  did not ﬁnd any signiﬁcant
association between injected drug use and other opportunistic
infections (data not shown). Mortality was  similar in the IDU
(1.9%;  2/104) and non-IDU (4.2%; 25/597) groups after 1 year of
follow-up  (p = 0.4073).
Discussion
In this study, the IDU group comprised a higher percentage
of  men  than non-IDU patients, a ﬁnding that is in accor-
dance with a previous report.3 Moreover, the IDU group was
younger,  which is also in line with a previous report6 but
not  with another one.3 CD4 cells are the main target of HIV
infection  and their reduced count is associated with disease
progression. We  found a lower CD4 count in the IDU group
compared with the non-IDU group, despite having similar viral
loads. Dronda et al.6 have shown long-term poorer recovery
of  CD4 cells despite successful virological suppression in IDU
patients.  Anemia is the commonest hematological abnormal-
ity  in HIV-infected patients and its incidence is associated
7,8with disease severity and mortality. Anemia was not higher
among  IDU than non-IDU patients, in disagreement with
data  shown by others.9 Besides anemia, thrombocytopenia is
often observed in HIV-infected patients. Approximately 40%
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of HIV patients present thrombocytopenia during the course
of  their illness.10 As with other HIV-associated cytopenias,
the etiology of thrombocytopenia is multifactorial. Megakary-
ocytes  express CD411 and CXCR-412 and, thereby, are targets
for  HIV. Besides, expression of viral proteins or altered anti-
gens  on the cell membrane make infected megakaryocytes
susceptible to immune attack.13 Furthermore, HCV infec-
tion,  commonly found in HIV-infected patients especially
among IDU, is a well-known cause of thrombocytopenia.14
In this study the percentage of HCV among IDU patients
was  inferior than previously reported.6,15 We found a higher
frequency of thrombocytopenia in IDU patients, but this ﬁnd-
ing  was  observed only in HCV infected patients. Tuberculosis
is  an endemic infection in Brazil, and its incidence, along
with  non-tuberculous mycobacterial infections, is increased
in  HIV patients, especially in the IDU group, a ﬁnding that
is  in accordance with other studies.16 Furthermore, the pro-
posal  of an inexpensive surrogate marker for AIDS severity,
such  as hemoglobin concentration and lymphocyte count,
could  be a useful tool for evaluations of AIDS severity in
developing countries, where the high prevalence of HIV and
low  ﬁnancial resources limit adequate disease monitoring.
In  conclusion, HIV-infected IDU patients tend to present
a  more  severe disease, as demonstrated by a higher rate
of  thrombocytopenia and more  profound immunosuppres-
sion.
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